---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014380"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:24:44.482698+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M

## Summary
- Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.
- Expected close April 15, 2024; $5M of proceeds to redeem Series A Preferred Stock; remainder for working capital.
- FY2023 revenue $1.5M (+57%); operating loss $25.1M (+40%); cash burn Q4 2023 $4.4M, Q1 2024 est. $3.8M.
- Bio-Rad partnership for transplant monitoring IP; GraftAssure product launch on track for Q2 2024.

## SEC filing metadata
- accession: 0001493152-24-014380
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 7.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014380
- JSON: https://secwatch.observer/filing/0001493152-24-014380.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014380.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported year ended December 31, 2023 results: revenue $1.5 million.
  - Period: year ended December 31, 2023
  - Revenue: $1.5 million
  - Result: reported results
  source text: commercial and regulatory milestones.” 2023 Fourth Quarter and Full-Year Financial Results Net revenue for the three months and year ended December 31, 2023, was $314,000 and $1.5 million, respectively, an increase of 15% compared to the fourth quarter 2022 and 57% compared to the full year 2022, due to increased revenue from Pharma Services. Cost of revenues for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm
- Material Agreements
  Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $15.8 million
  - Effective: 2024-04-11
  source text: On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.